Skip to search formSkip to main contentSkip to account menu

pirfenidone

Known as: 5-methyl-1-phenyl-2-(1H)-pyridone 
An orally active synthetic antifibrotic agent structurally similar to pyridine 2,4-dicarboxylate. Pirfenidone inhibits fibroblast, epidermal… 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (4)

AnalgesicsAnti-Inflammatory Agents, Non-SteroidalAntineoplastic AgentsPyridones

Narrower (1)

Deskar
NCIt Antineoplastic Agent Terminologypirfenidone 801 MG Oral Tablet [Esbriet]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Inflammation and immunity in IPF pathogenesis and treatment.
Highly Cited
2016
Highly Cited
2016
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
Objective. Systemic sclerosis-associated interstitial lung disease (SSc-ILD) shares a number of clinical features and pathogenic… 
Review
2014
Review
2014
The epithelium in idiopathic pulmonary fibrosis: breaking the barrier
Idiopathic pulmonary fibrosis is a progressive disease of unknown etiology characterized by a dysregulated wound healing response… 
Highly Cited
2013
Highly Cited
2013
Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells.
Pancreatic stellate cells (PSC), which are implicated in desmoplasia in pancreatic cancer, enhance the malignancy of cancer cells… 
Highly Cited
2011
Highly Cited
2011
Pirfenidone for diabetic nephropathy.
Pirfenidone is an oral antifibrotic agent that benefits diabetic nephropathy in animal models, but whether it is effective for… 
Highly Cited
2010
Highly Cited
2010
The multifaceted role of pirfenidone and its novel targets
BackgroundPirfenidone (PFD) is a molecule that exhibits antifibrotic properties in a variety of in vitro and animal models of… 
Highly Cited
2007
Highly Cited
2007
Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis.
BACKGROUND AND OBJECTIVES Pirfenidone is an orally available antifibrotic agent that has shown benefit in animal models of… 
Highly Cited
2001
Highly Cited
2001
Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin‐diabetic rats
Fibrosis leads to chronic impairment of cardiac and renal function and thus reversal of existing fibrosis may improve function… 
Highly Cited
1999
Highly Cited
1999
Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent , Pirfenidone Results of a Prospective , Open-label Phase II Study
Idiopathic pulmonary fibrosis (IPF) is a progressive clinical syndrome of unknown etiology and fatal outcome. Currently available… 
Highly Cited
1998
Highly Cited
1998
Pirfenidone improves renal function and fibrosis in the post-obstructed kidney.
BACKGROUND Pirfenidone (PFD) is a novel anti-fibrotic agent that can prevent and even reverse extracellular matrix accumulation… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)